Indices of insulin sensitivity, beta cell function and serum proinsulin levels in the polycystic ovary syndrome

Panidis, Dimitrios; Macut, Djuro; Farmakiotis, Dimitrios; Rousso, David; Kourtis, Anargyros; Katsikis, Ilias; Spanos, Nikolaos; Petakov, Мilan; Bjekić, Jelica; Damjanović, Svetozar

doi:10.1016/j.ejogrb.2005.12.016

Cited by 18 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in agreement with previous studies concerning diet-induced reduction of weight in women with PCOS (19,43) and is consistent with the findings of higher levels of T, but not D 4 A, in obese women with PCOS, compared with lean women with the syndrome (44). A possible explanation for these findings is the notion that an important portion of T in obese women is the product of D 4 A conversion in the abdominal fat (13,14,19).…”

Section: Panidis Orlistat and Diet In Pcos Fertil Steril 2008supporting

confidence: 93%

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Panidis

Farmakiotis

Rousso

et al. 2008

Fertility and Sterility

Self Cite

102

View full text Add to dashboard Cite

Section: Panidis Orlistat and Diet In Pcos Fertil Steril 2008supporting

confidence: 93%

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Panidis

Farmakiotis

Rousso

et al. 2008

Fertility and Sterility

Self Cite

102

View full text Add to dashboard Cite

“…IR has been proposed as a "second hit" that nonspecifically contributes to PCOS-associated follicular arrest (5,6,11). In the present study, the well-known (2,14,21) association between IR and obesity was confirmed; however, no independent significant association with PCOS was found, although a trend for higher HOMA-IR values in women with PCOS, especially its "severe" form, was observed (Tables 2 and 3). It should be noted, however, that these negative results may well have been limited by the wide spread of fasting indexes of IR values, which in small samples have been shown to be relatively inaccurate, compared with the "golden standard," i.e., the euglycemic hyperinsulinemic clamp (3).…”

Section: Discussionsupporting

confidence: 60%

Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels

Piouka

Farmakiotis²,

Katsikis³

et al. 2009

American Journal of Physiology-Endocrinology and Metabolism

Self Cite

283

193

View full text Add to dashboard Cite

The objective of the study was the comparison of anti-Müllerian hormone (AMH) levels among obese or overweight and normal-weight women with the four different polycystic ovary syndrome (PCOS) phenotypes and healthy control subjects. AMH levels were evaluated in four age- and body mass index (BMI)-matched groups of 25 normal-weight and 25 obese or overweight women each, belonging to the four main subsets of the syndrome resulting from combinations of the three diagnostic criteria [group 1: oligo- and/or anovulation (ANOV), hyperandrogenemia (HA), and polycystic ovaries (PCO) on ultrasonographic evaluation; group 2: ANOV and HA; group 3: HA and PCO, group 4: ANOV and PCO], and in 50 (25 obese or overweight and 25 normal weight) age- and BMI-matched healthy control subjects. Age, BMI, waist circumference, FSH, LH, prolactin, testosterone, Delta(4)-androstenedione, dehydroepiandrosterone-sulfate, 17alpha-OH-progesterone, fasting insulin, glucose, AMH, free androgen index, and homeostasis model assessment for insulin resistance index were analyzed. AMH levels were significantly higher in PCOS groups 1 and 2 compared with groups 3 and 4 and the control group and higher in PCOS groups 3 and 4 compared with the control group. AMH levels were significantly increased in normal-weight compared with obese and overweight women. AMH concentrations were independently predicted, in order of significance, by LH and testosterone levels, BMI (negatively), and the total number of follicles 2-9 mm in diameter. The differences in circulating AMH levels between the main phenotypic groups of PCOS women appear to reflect the severity of the syndrome, but are negatively affected by obesity. Increased LH levels might be the most significant independent link between PCOS-associated disorders of ovulation and the observed increase in circulating AMH concentration.

show abstract

“…145,152,153 Abdominal adiposity in women is usually associated with elevated circulating total and free testosterone. 154 Moreover, insulin resistance has been suggested to play an important role in the pathogenesis of PCOS.…”

Section: Metabolic Syndrome and Polycystic Ovarian Syndromementioning

confidence: 99%

Metabolic syndrome and cardiovascular disease

Qiao¹,

Gao²,

Zhang³

et al. 2007

Ann Clin Biochem

141

View full text Add to dashboard Cite

The clustering of metabolic and pathophysiological cardiovascular risk factors has long been recognized but it was Reaven who popularized the syndrome in the Banting lecture of 1988. Since 1999, several major international or national organizations proposed their own definitions for the syndrome, named the metabolic syndrome. The prevalence of the metabolic syndrome varies according to definition, ethnicity and gender. The prevalence is under 20% among Chinese and Korean people but over 50% among Maori and Pacific Islanders in New Zealand. People with the metabolic syndrome have 50-60% higher cardiovascular risk than those without. The absolute cardiovascular risk of the metabolic syndrome, however, is not necessarily higher than those of its individual components. The pathogenesis underlying the clustering of cardiovascular risk factors remains unclear. Factors including genetic disposition, obesity, insulin resistance and inflammation have been suggested as being involved. Since the metabolic syndrome is multifactorial in origin, strategies for reducing cardiovascular risk in individuals with the metabolic syndrome involve the management of multiple risks. Lifestyle changes are an effective first-line management; pharmacological interventions for hypertension, diabetes and dyslipidaemia are in accordance with established guidelines. Pharmacological and surgical therapies for obesity are effective in selected patients. In this article we discuss the definitions, prevalence, pathogenesis and management of the metabolic syndrome in relation to cardiovascular risk.

show abstract

Indices of insulin sensitivity, beta cell function and serum proinsulin levels in the polycystic ovary syndrome

Cited by 18 publications

References 35 publications

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels

Metabolic syndrome and cardiovascular disease

Contact Info

Product

Resources

About